Can DIO2 rs225014 CT reduce local T4-to-T3 conversion in tissues?

The DIO2 gene encodes type 2 deiodinase (D2), the primary enzyme responsible for converting intracellular thyroxine (T4) into the active triiodothyronine (T3) hormone within key target tissues, including the brain, skeletal muscle, and brown adipose tissue.

Mechanistic explanations

• Protein mislocalization: The DIO2 rs225014 (Thr92Ala) polymorphism alters cellular trafficking of the D2 enzyme. The Ala92 variant causes the protein to accumulate abnormally within the trans-Golgi network rather than reaching its functional destination, which triggers endoplasmic reticulum (ER) stress.
• Reduced enzymatic activity: This intracellular mislocalization and subsequent ER stress render the D2 enzyme inactive. The heterozygous CT genotype exhibits an intermediate, mildly reduced baseline enzymatic efficiency compared to the wild-type (TT) genotype, directly impairing the rate of local outer-ring deiodination of T4.
• Attenuated signaling: This deficit reduces intracellular T3 concentrations, leading to diminished nuclear T3-dependent receptor signaling in tissues dependent on local D2 conversion.

Clinical implications

• Normal systemic markers: This localized deficit in T3 signaling characteristically co-occurs alongside normal systemic thyroid panels.
• Pituitary feedback loop: Because pituitary deiodination can maintain sufficient local T3 production to provide normal feedback to the hypothalamus and pituitary, serum TSH and free T4 levels remain within reference ranges.
• Tissue-specific hypothyroidism: This regulatory mismatch allows localized, tissue-level hypothyroidism to persist in peripheral organs even when standard blood tests indicate a clinically euthyroid state.

Bottom line

• The DIO2 rs225014 CT genotype reduces type 2 deiodinase activity through ER stress and Golgi mislocalization, causing a localized intracellular T3 deficiency that is typically masked by clinically normal serum TSH and free T4 levels.